Current Advances in Idiopathic Pulmonary Fibrosis: The pathogenesis, Therapeutic Strategies and Candidate Molecules

References

• Nalysnyk L , Cid-RuzafaJ, RotellaPet al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur. Respir. Rev.21(126), 355–361 (2012).
   PubMedGoogle Scholar
• Hutchinson J , FogartyA, HubbardRet al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur. Respir. J.46(3), 795–806 (2015).
   PubMed Web of Science ®Google Scholar
• Olson AL , GiffordAH, InaseNet al. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur. Respir. Rev.27(150), 180077 (2018).
   PubMed Web of Science ®Google Scholar
• Ley B , CollardHR, KingTEJr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.183(4), 431–440 (2011).
   PubMed Web of Science ®Google Scholar
• De Vries J , KesselsBL, DrentM. Quality of life of idiopathic pulmonary fibrosis patients. Eur. Respir. J.17(5), 954–961 (2001).
   PubMed Web of Science ®Google Scholar
• Song JW , HongSB, LimCMet al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur. Respir. J.37(2), 356–363 (2011).
   PubMed Web of Science ®Google Scholar
• Collard HR , RyersonCJ, CorteTJet al. Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report. Am. J. Respir. Crit. Care Med.194(3), 265–275 (2016).
   PubMed Web of Science ®Google Scholar
• Society AT . American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med.161(2 Pt 1), 646–664 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson MA , KwanS, SnellNJet al. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax44(4), 280–288 (1989).
   PubMed Web of Science ®Google Scholar
• Raghu G , DepasoWJ, CainKet al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis.144(2), 291–296 (1991).
   PubMed Web of Science ®Google Scholar
• van Oortegem K , WallaertB, MarquetteCHet al. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur. Respir. J.7(11), 1950–1957 (1994).
   PubMed Web of Science ®Google Scholar
• Selman M , CarrilloG, SalasJet al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest114(2), 507–512 (1998).
   PubMed Web of Science ®Google Scholar
• Flaherty KR , ToewsGB, LynchJP3rdet al. Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival. Am. J. Med.110(4), 278–282 (2001).
   PubMed Web of Science ®Google Scholar
• Selman M , KingTE, PardoA. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med.134(2), 136–151 (2001).
   PubMed Web of Science ®Google Scholar
• Mura M , BelmonteG, FantiSet al. Inflammatory activity is still present in the advanced stages of idiopathic pulmonary fibrosis. Respirology10(5), 609 (2005).
   PubMed Web of Science ®Google Scholar
• Desai O , WinklerJ, MinasyanMet al. The role of immune and inflammatory cells in idiopathic pulmonary fibrosis. Front. Med. (Lausanne)5, 43 (2018).
   PubMed Web of Science ®Google Scholar
• Heukels P , MoorCC, vonder Thusen JHet al. Inflammation and immunity in IPF pathogenesis and treatment. Respir. Med.147, 79–91 (2019).
   PubMed Web of Science ®Google Scholar
• Mayadas TN , CullereX, LowellCA. The multifaceted functions of neutrophils. Annu. Rev. Pathol.9, 181–218 (2014).
   PubMed Web of Science ®Google Scholar
• Duru N , WolfsonB, ZhouQ. Mechanisms of the alternative activation of macrophages and non-coding RNAs in the development of radiation-induced lung fibrosis. World J. Biol. Chem.7(4), 231–239 (2016).
   PubMedGoogle Scholar
• Vassilakis DA , SourvinosG, SpandidosDAet al. Frequent genetic alterations at the microsatellite level in cytologic sputum samples of patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.162(3 Pt 1), 1115 (2000).
   PubMed Web of Science ®Google Scholar
• Demopoulos K , ArvanitisDA, VassilakisDAet al. MYCL1, FHIT, SPARC, p16INK4 and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. J. Cell. Mol. Med.6(2), 215–222 (2002).
   PubMed Web of Science ®Google Scholar
• Armanios MY , ChenJJ-L, CoganJDet al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med.356(13), 1317–1326 (2007).
   PubMed Web of Science ®Google Scholar
• Alder JK , ChenJJ, LancasterLet al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl Acad. Sci. USA105(35), 13051–13056 (2008).
   PubMed Web of Science ®Google Scholar
• Kuwano K , HagimotoN, MaeyamaTet al. Mitochondria-mediated apoptosis of lung epithelial cells in idiopathic interstitial pneumonias. Lab. Invest.82(12), 1695–1706 (2002).
   PubMed Web of Science ®Google Scholar
• Araya J , KojimaJ, TakasakaNet al. Insufficient autophagy in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol.304(1), L56–69 (2013).
   PubMed Web of Science ®Google Scholar
• Su X . Leading neutrophils to the alveoli: who is the guider?Am. J. Respir. Crit. Care Med.186(6), 472–473 (2012).
   PubMed Web of Science ®Google Scholar
• Noth I , ZhangY, MaS-Fet al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir. Med.1(4), 309–317 (2013).
   PubMed Web of Science ®Google Scholar
• Fingerlin TE , MurphyE, ZhangWet al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat. Genet.45(6), 613–620 (2013).
   PubMed Web of Science ®Google Scholar
• Selman M , PardoA. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc. Am. Thorac. Soc.3(4), 364–372 (2006).
   PubMedGoogle Scholar
• Willis BC , LieblerJM, LubyphelpsKet al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol.166(5), 1321–1332 (2005).
   PubMed Web of Science ®Google Scholar
• Willis BC . Epithelial origin of myofibroblasts during fibrosis in the lung. Proc. Am.Thorac. Soc.3(4), 377–382 (2006).
   PubMedGoogle Scholar
• Moore MW , HerzogEL. Regulation and relevance of myofibroblast responses in idiopathic pulmonary fibrosis. Curr. Pathobiol. Rep.1(3), 199–208 (2013).
   PubMedGoogle Scholar
• Kapanci Y , DesmouliereA, PacheJCet al. Cytoskeletal protein modulation in pulmonary alveolar myofibroblasts during idiopathic pulmonary fibrosis. Possible role of transforming growth factor beta and tumor necrosis factor α. Am. J. Respir. Crit. Care Med.152(1), 2163–2169 (1995).
   PubMedGoogle Scholar
• Giaid A , MichelRP, StewartDJet al. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet341(8860), 1550–1554 (1993).
   PubMed Web of Science ®Google Scholar
• Antoniades HN , BravoMA, AvilaREet al. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J. Clin. Invest.86(4), 1055 (1990).
   PubMed Web of Science ®Google Scholar
• Pan LH , YamauchiK, UzukiMet al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur. Respir. J.17(6), 1220–1227 (2001).
   PubMed Web of Science ®Google Scholar
• Willis BC , LieblerJM, Luby-PhelpsKet al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1 : potential role in idiopathic pulmonary fibrosis. Am. J. Pathol.166(5), 1321–1332 (2005).
   PubMed Web of Science ®Google Scholar
• Peyser R , MacDonnellS, GaoYet al. Defining the activated fibroblast population in lung fibrosis using single-cell sequencing. Am. J. Respir. Cell Mol. Biol.61(1), 74–85 (2019).
   PubMed Web of Science ®Google Scholar
• Im J , LawrenceJ, SeeligDet al. FoxM1-dependent RAD51 and BRCA2 signaling protects idiopathic pulmonary fibrosis fibroblasts from radiation-induced cell death. Cell Death Dis.9(6), 584 (2018).
   PubMedGoogle Scholar
• Sontake V , KasamRK, SinnerDet al. Wilms’ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease. JCI Insight3(16), e121252 (2018).
   PubMed Web of Science ®Google Scholar
• Kinnula VL , FattmanCL, TanRJet al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am. J. Respir. Crit. Care Med.172(4), 417–422 (2005).
   PubMed Web of Science ®Google Scholar
• Kliment CR , OuryTD. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med.49(5), 707–717 (2010).
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y , KawashimaT, KuwabaraRet al. Change in serum marker of oxidative stress in the progression of idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther.32, 1–6 (2015).
   PubMed Web of Science ®Google Scholar
• Hecker L , VittalR, JonesTet al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med.15(9), 1077–1081 (2009).
   PubMed Web of Science ®Google Scholar
• Bernard K , LogsdonNJ, MiguelVet al. NADPH oxidase 4 (Nox4) suppresses mitochondrial biogenesis and bioenergetics in lung fibroblasts via a nuclear factor erythroid-derived 2-like 2 (Nrf2)-dependent pathway. J. Biol. Chem.292(7), 3029–3038 (2017).
   PubMed Web of Science ®Google Scholar
• Cross CE , Vander Vliet A, O’NeillCAet al. Oxidants, antioxidants, and respiratory tract lining fluids. Environ. Health Perspect.102(Suppl. 10), 185–191 (1995).
   Google Scholar
• Shukla A , Ramos-NinoM, MossmanB. Cell signaling and transcription factor activation by asbestos in lung injury and disease. Int. J. Biochem. Cell Biol.35(35), 1198–1209 (2003).
   PubMedGoogle Scholar
• Murrell GA , FrancisMJ, BromleyL. Modulation of fibroblast proliferation by oxygen free radicals. Biochem. J.265(3), 659–665 (1990).
   PubMed Web of Science ®Google Scholar
• Waghray M , CuiZ, HorowitzJCet al. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J.19(7), 854 (2005).
   PubMed Web of Science ®Google Scholar
• Lv M , ChenZ, HuGet al. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discov. Today20(3), 332–346 (2015).
   PubMed Web of Science ®Google Scholar
• Rantapaa-Dahlqvist S , BomanK, TarkowskiAet al. Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann. Rheum. Dis.66(1), 121–123 (2007).
   PubMed Web of Science ®Google Scholar
• Ip WK , WongCK, LamCW. Interleukin (IL)-4 and IL-13 up-regulate monocyte chemoattractant protein-1 expression in human bronchial epithelial cells: involvement of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2 and Janus kinase-2 but not c-Jun NH2-terminal kinase 1/2 signalling pathways. Clin. Exp. Immunol.145(1), 162–172 (2006).
   PubMed Web of Science ®Google Scholar
• Suga M , IyonagaK, IchiyasuHet al. Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur. Respir. J.14(2), 376 (1999).
   PubMed Web of Science ®Google Scholar
• Moore BB , KolodsickJE, ThannickalVJet al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol.166(3), 675–684 (2005).
   PubMed Web of Science ®Google Scholar
• Moore BB , MurrayL, DasAet al. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am. J. Respir. Cell Mol. Biol.35(2), 175–181 (2006).
   PubMed Web of Science ®Google Scholar
• Raghu G , MartinezFJ, BrownKKet al. CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a Phase II trial of carlumab. Eur. Respir. J.46(6), 1740–1750 (2015).
   PubMed Web of Science ®Google Scholar
• Horton M , SantopietroV, MathewLet al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann. Intern. Med.157(6), 398–406 (2012).
   PubMed Web of Science ®Google Scholar
• Raghu G , vanden Blink B, HamblinMJet al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA319(22), 2299–2307 (2018).
   PubMed Web of Science ®Google Scholar
• Raghu G , vanden Blink B, HamblinMJet al. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir. Med.7(8), 657–664 (2019)
   PubMed Web of Science ®Google Scholar
• Parker JM , GlaspoleIN, LancasterLHet al. A Phase II randomized controlled study of tralokinumab in subjects with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.197(1), 94–103 (2018).
   PubMed Web of Science ®Google Scholar
• Raghu G , RicheldiL, CrestaniBet al. SAR156597 in idiopathic pulmonary fibrosis: a Phase II placebo-controlled study (DRI11772). Eur. Respir. J.52(6), 1801130 (2018).
   PubMed Web of Science ®Google Scholar
• Demedts M , BehrJ, BuhlRet al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med.353(21), 2229–2242 (2005).
   PubMed Web of Science ®Google Scholar
• Behr J , DemedtsM, BuhlRet al. Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial. Respir. Res.10, 101 (2009).
   PubMed Web of Science ®Google Scholar
• Raghu G , AnstromKJ, KingTEJret al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med.366(21), 1968–1977 (2012).
   PubMed Web of Science ®Google Scholar
• Martinez FJ , de AndradeJA, AnstromKJet al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med.370(22), 2093–2101 (2014).
   PubMed Web of Science ®Google Scholar
• Raghu G , BrownKK, BradfordWZet al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med.350(2), 125–133 (2004).
   PubMed Web of Science ®Google Scholar
• King TE Jr , AlberaC, BradfordWZet al. Effect of interferon γ-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet374(9685), 222–228 (2009).
   PubMed Web of Science ®Google Scholar
• Maher TM , vander Aar EM, Vande Steen Oet al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a Phase IIa randomised placebo-controlled trial. Lancet Respir. Med.6(8), 627–635 (2018).
   PubMed Web of Science ®Google Scholar
• Palmer SM , SnyderL, ToddJLet al. Randomized, double-blind, placebo-controlled, Phase II Trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis. Chest154(5), 1061–1069 (2018).
   PubMed Web of Science ®Google Scholar
• Averill F , AlbertsonTE, BaratzDMet al. A Phase IItrial of KD025 to assess efficacy, safety and tolerability in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.197, A5927 (2018).
   Google Scholar
• Raghu G , ScholandMB, de AndradeJet al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur. Respir. J.47(5), 1481–1491 (2016).
   PubMed Web of Science ®Google Scholar
• Jl VDV , YeY, NolinJDet al. JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clin. Trans. Med.5(1), 36 (2016).
   PubMedGoogle Scholar
• Hirani N , NicolL, MackinnonACet al. TD139, A novel inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). Results from the first in (IPF) patients study. QJM Monthly J. Assoc. Phys.109(Suppl. 1), S16–S16 (2016).
   Google Scholar
• Lukey PT , HarrisonSA, YangSet al. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. Eur. Respir. J.53(3), 1801992 (2019).
   PubMed Web of Science ®Google Scholar
• Malouf MA , HopkinsP, SnellGet al. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology16(5), 776–783 (2011).
   PubMed Web of Science ®Google Scholar
• Noth I , AnstromKJ, CalvertSBet al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.186(1), 88–95 (2012).
   PubMed Web of Science ®Google Scholar
• Justice JN , NambiarAM, TchkoniaTet al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine40, 554–563 (2019).
   PubMed Web of Science ®Google Scholar
• Raghu G , Million-RousseauR, MorgantiAet al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur. Respir. J.42(6), 1622–1632 (2013).
   PubMed Web of Science ®Google Scholar
• King TE , BehrJ, BrownKKet al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.177(1), 75–81 (2008).
   PubMed Web of Science ®Google Scholar
• King TE Jr , BrownKK, RaghuGet al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.184(1), 92–99 (2011).
   PubMed Web of Science ®Google Scholar
• Khalil N , ManganasH, RyersonCJet al. Phase II clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur. Respir. J.53(3), 1800663–1800672 (2019).
   PubMed Web of Science ®Google Scholar
• Sime PJ , O’ReillyKM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin. Immunol.99(3), 308–319 (2001).
   PubMed Web of Science ®Google Scholar
• Franks ME , MacphersonGR, FiggWD. Thalidomide. Lancet363(9423), 1802–1811 (2004).
   PubMed Web of Science ®Google Scholar
• Singhal S , MehtaJ, DesikanRet al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med.341(21), 1565–1571 (1999).
   PubMed Web of Science ®Google Scholar
• Eisen T , BoshoffC, MakIet al. Continuous low dose Thalidomide: a Phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br. J. Cancer82(4), 812–817 (2000).
   PubMed Web of Science ®Google Scholar
• Figg WD , DahutW, DurayPet al. A randomized Phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res.7(7), 1888–1893 (2001).
   PubMed Web of Science ®Google Scholar
• Ye Q , ChenB, TongZet al. Thalidomide reduces IL-18, IL-8 and TNF-α release from alveolar macrophages in interstitial lung disease. Eur. Respir. J.28(4), 824–831 (2006).
   PubMed Web of Science ®Google Scholar
• Horton MR , DanoffSK, LechtzinN. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax63(8), 749 (2008).
   PubMed Web of Science ®Google Scholar
• Cox N , PillingD, GomerRH. Serum amyloid P: a systemic regulator of the innate immune response. J. Leukoc. Biol.96(5), 739–743 (2014).
   PubMed Web of Science ®Google Scholar
• Pilling D , RoifeD, WangMet al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J. Immunol.179(6), 4035–4044 (2007).
   PubMed Web of Science ®Google Scholar
• Pilling D , BuckleyCD, SalmonMet al. Inhibition of fibrocyte differentiation by serum amyloid P. J. Immunol.171(10), 5537 (2003).
   PubMed Web of Science ®Google Scholar
• Moreira AP , CavassaniKA, HullingerRet al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. J. Allergy Clin. Immunol.126(4), 712e7–721e7 (2010).
   Web of Science ®Google Scholar
• Murray LA , ChenQ, KramerMSet al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by Serum amyloid P. Int. J. Biochem. Cell Biol.43(1), 154–162 (2011).
   PubMed Web of Science ®Google Scholar
• van den Blink B , DillinghMR, GinnsLCet al. Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. Eur. Respir. J.47(3), 889–897 (2016).
   PubMed Web of Science ®Google Scholar
• Jakubzick C , ChoiES, JoshiBHet al. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J. Immunol.171(5), 2684–2693 (2003).
   PubMed Web of Science ®Google Scholar
• Rahman I , SkwarskaE, HenryMet al. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic. Biol. Med.27(1–2), 60–68 (1999).
   PubMed Web of Science ®Google Scholar
• Zafarullah M , LiWQ, SylvesterJet al. Molecular mechanisms of N -acetylcysteine actions. Cell. Mol. Life Sci.60(1), 6 (2003).
   PubMed Web of Science ®Google Scholar
• Ates B , AbrahamL, ErcalN. Antioxidant and free radical scavenging properties of N-acetylcysteine amide (NACA) and comparison with N-acetylcysteine (NAC). Free Radic. Res.42(4), 372–327 (2008).
   PubMed Web of Science ®Google Scholar
• Tomioka H , KuwataY, ImanakaKet al. A pilot study of aerosolized N‐acetylcysteine for idiopathic pulmonary fibrosis. Respirology10(4), 449–455 (2005).
   PubMed Web of Science ®Google Scholar
• Raghu G , RochwergB, ZhangYet al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med.192(2), e3–e19 (2015).
   PubMed Web of Science ®Google Scholar
• Spagnolo P , BonellaF, MaherTM. New guideline on treatment of idiopathic pulmonary fibrosis. Lancet Respir. Med.3(9), e31–e32 (2015).
   PubMed Web of Science ®Google Scholar
• Amara N , GovenD, ProstFet al. NOX4/NADPH oxidase expression is increased in pulmonary fibroblasts from patients with idiopathic pulmonary fibrosis and mediates TGF 1-induced fibroblast differentiation into myofibroblasts. Thorax65(8), 733–738 (2010).
   PubMed Web of Science ®Google Scholar
• Carnesecchi S , DeffertC, DonatiYet al. A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid. Redox Signal15(3), 607–619 (2011).
   PubMed Web of Science ®Google Scholar
• Laleu B , GagginiF, OrchardMet al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J. Med. Chem.53(21), 7715–7730 (2010).
   PubMed Web of Science ®Google Scholar
• Aoyama T , PaikYH, WatanabeSet al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology56(6), 2316–2327 (2012).
   PubMed Web of Science ®Google Scholar
• Hecker L , ChengJ, ThannickalVJ. Targeting NOX enzymes in pulmonary fibrosis. Cell. Mol. Life Sci.69(14), 2365–2371 (2012).
   PubMed Web of Science ®Google Scholar
• Altenhofer S , RadermacherKA, KleikersPWet al. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid. Redox Signal23(5), 406–427 (2015).
   PubMed Web of Science ®Google Scholar
• Jarman ER , KhambataVS, CopeCet al. An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model. Am. J. Respir. Cell Mol. Biol.50(1), 158–169 (2014).
   PubMed Web of Science ®Google Scholar
• Farkas L , GauldieJ, VoelkelNFet al. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am. J. Respir. Cell Mol. Biol.45(1), 1–15 (2011).
   PubMed Web of Science ®Google Scholar
• Green DE , MurphyTC, KangBYet al. The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. Am. J. Respir. Cell Mol. Biol.47(5), 718–726 (2012).
   PubMed Web of Science ®Google Scholar
• Hengsawas Surasarang S , FlorovaG, KomissarovAAet al. Formulation for a novel inhaled peptide therapeutic for idiopathic pulmonary fibrosis. Drug Dev. Ind. Pharm.44(2), 184–198 (2017).
   PubMed Web of Science ®Google Scholar
• El Agha E , MoiseenkoA, KheirollahiVet al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell20(2), 261e3–273e3 (2017).
   Web of Science ®Google Scholar
• Kheirollahi V , WasnickRM, BiasinVet al. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nat. Commun.10(1), 2987 (2019).
   PubMedGoogle Scholar
• Sato N , TakasakaN, YoshidaMet al. Metformin attenuates lung fibrosis development via NOX4 suppression. Respir. Res.17(1), 107 (2016).
   PubMedGoogle Scholar
• Bogatkevich GS , Ludwicka-BradleyA, SilverRM. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum.60(11), 3455–3464 (2009).
   PubMed Web of Science ®Google Scholar
• Bogatkevich GS , Ludwicka-BradleyA, NietertPJet al. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum.63(5), 1416–1425 (2011).
   PubMed Web of Science ®Google Scholar
• Chaudhary NI , RothGJ, HilbergFet al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J.29(5), 976–985 (2007).
   PubMed Web of Science ®Google Scholar
• Meng J , ZouY, HuCet al. Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway. Shock38(5), 567–573 (2012).
   PubMed Web of Science ®Google Scholar
• Chen J , LuMM, LiuBet al. Synthesis and structure-activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agents. Bioorg. Med. Chem. Lett.22(6), 2300–2302 (2012).
   PubMed Web of Science ®Google Scholar
• Wu L , LiuB, LiQet al. Design, synthesis and anti-fibrosis activity study of N(1)-substituted phenylhydroquinolinone derivatives. Molecules17(2), 1373–1387 (2012).
   PubMed Web of Science ®Google Scholar
• Schroder K , HertzogPJ, RavasiTet al. Interferon-γ: an overview of signals, mechanisms and functions. J. Leukoc. Biol.75(2), 163–189 (2004).
   PubMed Web of Science ®Google Scholar
• Horan GS , WoodS, OnaVet al. Partial inhibition of integrin α(v)β6 prevents pulmonary fibrosis without exacerbating inflammation. Am. J. Respir. Crit. Care Med.177(1), 56–65 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson NA , CampbellIB, FallonBJet al. Synthesis and determination of absolute configuration of a non-peptidic α v β 6 integrin antagonist for the treatment of idiopathic pulmonary fibrosis. Org. Biomol. Chem.14(25), 5992–6009 (2016).
   PubMed Web of Science ®Google Scholar
• Tager AM , LaCameraP, SheaBSet al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med.14(1), 45–54 (2008).
   PubMed Web of Science ®Google Scholar
• Oikonomou N , MouratisMA, TzouvelekisAet al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol.47(5), 566–574 (2012).
   PubMed Web of Science ®Google Scholar
• Desroy N , HoussemanC, BockXet al. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methyli midazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a first-in-class autotaxin inhibitor undergoing clinical evaluation for the treatment of idiopathic pulmonary fibrosis. J. Med. Chem.60(9), 3580–3590 (2017).
   PubMed Web of Science ®Google Scholar
• Swaney JS , ChapmanC, CorreaLDet al. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br. J. Pharmacol.160(7), 1699–1713 (2010).
   PubMed Web of Science ®Google Scholar
• Knipe RS , TagerAM, LiaoJK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol. Rev.67(1), 103–117 (2015).
   PubMed Web of Science ®Google Scholar
• Boerma M , FuQ, WangJet al. Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin. Blood Coagul. Fibrinolysis19(7), 709–718 (2008).
   PubMed Web of Science ®Google Scholar
• Mageto Y , FlahertyK, BrownKet al. Safety and tolerability of human monoclonal antibody FG-3019, anti-connective tissue growth factor, in patients with idiopathic pulmonary fibrosis. Chest126(4), 773Sa (2004).
   Web of Science ®Google Scholar
• Rothberg KG , HeuserJE, DonzellWCet al. Caveolin, a protein component of caveolae membrane coats. Cell68(4), 673–682 (1992).
   PubMed Web of Science ®Google Scholar
• Mineo C , JamesGL, SmartEJet al. Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane. J. Biol. Chem.271(20), 11930–11935 (1996).
   PubMed Web of Science ®Google Scholar
• Liu P , YingY, KoYGet al. Localization of platelet-derived growth factor-stimulated phosphorylation cascade to caveolae. J. Biol. Chem.271(17), 10299–10303 (1996).
   PubMed Web of Science ®Google Scholar
• Wang XM , ZhangY, KimHPet al. Caveolin-1: a critical regulator of lung fibrosis in idiopathic pulmonary fibrosis. J. Exp. Med.203(13), 2895–2906 (2006).
   PubMed Web of Science ®Google Scholar
• Okamoto T , SchlegelA, SchererPEet al. Caveolins, a family of scaffolding proteins for organizing ‘preassembled signaling complexes’ at the plasma membrane. J. Biol. Chem.273(10), 5419–5422 (1998).
   PubMed Web of Science ®Google Scholar
• Cohen AW , HnaskoR, SchubertWet al. Role of caveolae and caveolins in health and disease. Physiol. Rev.84(4), 1341–1379 (2004).
   PubMed Web of Science ®Google Scholar
• Tourkina E , RichardM, GöözPet al. Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am. J. Physiol. Lung Cell Mol. Physiol.294(5), 843–861 (2008).
   PubMed Web of Science ®Google Scholar
• Yoshida K , KuwanoK, HagimotoNet al. MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis. J. Pathol.198(3), 388–396 (2002).
   PubMed Web of Science ®Google Scholar
• Plantevin KV , NadolnyL, DelgadoMet al. Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg. Med. Chem. Lett.22(3), 1433–1438 (2012).
   PubMed Web of Science ®Google Scholar
• Ye Y , KongL, AssafMet al. Safety, tolerability, and pharmacokinetics of ascending single oral doses of CC-930, a novel JNK inhibitor in healthy subjects. Clin. Pharmacol. Ther.89 (2011).
   PubMedGoogle Scholar
• Nishi Y , SanoH, KawashimaTet al. Role of galectin-3 in human pulmonary fibrosis. Allergol. Int.56(1), 57–65 (2007).
   PubMedGoogle Scholar
• Mackinnon AC , GibbonsMA, FarnworthSLet al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am. J. Respir. Crit. Care Med.185(5), 537–546 (2012).
   PubMed Web of Science ®Google Scholar
• Hsieh TJ , LinHY, TuZet al. Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors. Sci. Rep.6, 29457 (2016).
   PubMed Web of Science ®Google Scholar
• Garcia-Sancho Figueroa MC , CarrilloG, Perez-PadillaRet al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir. Med.104(2), 305–309 (2010).
   PubMed Web of Science ®Google Scholar
• Genovese T , CuzzocreaS, DiPaola Ret al. Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur. Respir. J.25(2), 225–234 (2005).
   PubMed Web of Science ®Google Scholar
• Burgess HA , DaughertyLE, ThatcherTHet al. PPAR-γ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol.288(6), L1146–L1153 (2005).
   PubMed Web of Science ®Google Scholar
• Ballester B , MilaraJ, CortijoJ. Idiopathic pulmonary fibrosis and lung cancer: mechanisms and molecular targets. Int.J. Mol. Sci.20(3), 593 (2019).
   PubMed Web of Science ®Google Scholar
• Mayer IA , ArteagaCL. The PI3K/AKT pathway as a target for cancer treatment. Annu. Rev. Med.67(1), 11 (2015).
   PubMedGoogle Scholar
• White ES , AtraszRG, HuBet al. Negative regulation of myofibroblast differentiation by PTEN (phosphatase and tensin homolog deleted on chromosome 10). Am. J. Respir. Crit. Care Med.173(1), 112 (2006).
   PubMed Web of Science ®Google Scholar
• Xia H , KhalilW, KahmJet al. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am. J. Pathol.176(6), 2626–2637 (2010).
   PubMed Web of Science ®Google Scholar
• Lu Y , AzadN, WangLet al. Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production. Am. J. Respir. Cell Mol. Biol.42(4), 432–441 (2010).
   PubMed Web of Science ®Google Scholar
• Conte E , FrucianoM, FagoneEet al. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PLoS ONE6(10), e24663 (2011).
   PubMed Web of Science ®Google Scholar
• Conte E , GiliE, FrucianoMet al. PI3K p110gamma overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition. Lab. Invest.93(5), 566–576 (2013).
   PubMed Web of Science ®Google Scholar
• Hardie WD. Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol.286(4), 741–749 (2003).
   Web of Science ®Google Scholar
• Le Cras TD , KorfhagenTR, DavidsonCet al. Inhibition of PI3K by PX-866 prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am. J. Pathol.176(2), 679–686 (2010).
   PubMed Web of Science ®Google Scholar
• Knight SD , AdamsND, BurgessJLet al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med. Chem. Lett.1(1), 39–43 (2010).
   PubMed Web of Science ®Google Scholar
• Mercer PF , WoodcockHV, EleyJDet al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax71(8), 701–711 (2016).
   PubMed Web of Science ®Google Scholar
• Hubbard RB , SmithC, LeJeune Iet al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am. J. Respir. Crit. Care Med.178(12), 1257–1261 (2008).
   PubMed Web of Science ®Google Scholar
• Sode BF , DahlM, NielsenSFet al. Venous thromboembolism and risk of idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med.181(10), 1085–1092 (2010).
   PubMed Web of Science ®Google Scholar
• Sprunger DB , OlsonAL, HuieTJet al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur. Respir. J.39(1), 125–132 (2012).
   PubMed Web of Science ®Google Scholar
• Kotani I , SatoA, HayakawaHet al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb. Res.77(6), 493 (1995).
   PubMed Web of Science ®Google Scholar
• Fujii M , HayakawaH, UranoT. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb. Res.99(2), 111–117 (2000).
   PubMed Web of Science ®Google Scholar
• Navaratnam V , FogartyAW, McKeeverTet al. Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study. Thorax69(3), 207–215 (2014).
   PubMed Web of Science ®Google Scholar
• Holbrook AM , PereiraJA, LabirisRet al. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med.165(10), 1095–1106 (2005).
   PubMed Web of Science ®Google Scholar
• Kubo H , NakayamaK, YanaiMet al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest128(3), 1475–1482 (2005).
   PubMed Web of Science ®Google Scholar
• Kreuter M , WijsenbeekMS, VasakovaMet al. Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur. Respir. J.47(6), 1776–1784 (2016).
   PubMed Web of Science ®Google Scholar
• Bogatkevich GS , TourkinaE, SilverRMet al. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J. Biol. Chem.276(48), 45184–45192 (2001).
   PubMed Web of Science ®Google Scholar
• Howell DC , LaurentGJ, ChambersRC. Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis. Biochem. Soc. Trans.30(2), 211 (2002).
   PubMedGoogle Scholar
• Shea BS , ProbstCK, BrazeePLet al. Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight2(9), 86608 (2017).
   PubMed Web of Science ®Google Scholar
• Sorbera LA , BozzoJ, CastañerJ. Dabigatran/Dabigatran etexilate. Drugs of the Future30(9), 877 (2005).
   Web of Science ®Google Scholar
• van Ryn J , StangierJ, HaertterSet al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost.103(6), 1116–1127 (2010).
   PubMed Web of Science ®Google Scholar
• Blommel ML , BlommelAL. Dabigatran etexilate: A novel oral direct thrombin inhibitor. Am. J. Health Syst. Pharm.68(16), 1506–1519 (2011).
   PubMed Web of Science ®Google Scholar
• Scotton CJ , KrupiczojcMA, KönigshoffMet al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J. Clin. Invest.119(9), 2550–2563 (2009).
   PubMed Web of Science ®Google Scholar
• Blanc-Brude OP , ChambersRC, LeoniPet al. Factor Xa is a fibroblast mitogen via binding to effector-cell protease receptor-1 and autocrine release of PDGF. Am. J. Physiol. Cell Physiol.281(2), C681–C689 (2001).
   PubMed Web of Science ®Google Scholar
• Blanc-Brude OP , ArcherF, LeoniPet al. Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp. Cell Res.304(1), 16–27 (2005).
   PubMed Web of Science ®Google Scholar
• Hong IS , CoeHV, CatanzaroLM. Macitentan for the treatment of pulmonary arterial hypertension. Ann. Pharmacother.48(4), 538–547 (2014).
   PubMed Web of Science ®Google Scholar
• Gagnon L , LeducM, ThibodeauJFet al. A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and GPR84. Am. J. Pathol.188(5), 1132–1148 (2018).
   PubMed Web of Science ®Google Scholar
• Coward WR , SainiG, JenkinsG. The pathogenesis of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis.4(6), 367–388 (2010).
   PubMedGoogle Scholar
• Allen JT , SpiteriMA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir. Res.3, 13 (2002).
   PubMed Web of Science ®Google Scholar
• Roth GJ , BinderR, ColbatzkyFet al. Nintedanib: from discovery to the clinic. J. Med. Chem.58(3), 1053–1063 (2015).
   PubMed Web of Science ®Google Scholar
• Richeldi L , CostabelU, SelmanMet al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N. Engl. J. Med.365(12), 1079–1087 (2011).
   PubMed Web of Science ®Google Scholar
• Richeldi L , du BoisRM, RaghuGet al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med.370(22), 2071–2082 (2014).
   PubMed Web of Science ®Google Scholar
• Richeldi L , CottinV, FlahertyKRet al. Design of the INPULSIS trials: two Phase III trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir. Med.108(7), 1023–1030 (2014).
   PubMed Web of Science ®Google Scholar
• Corte T , BonellaF, CrestaniBet al. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir. Res.16(1), 116 (2015).
   PubMedGoogle Scholar
• Misra HP , RabideauC. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell. Biochem.204(1/2), 119–126 (2000).
   PubMed Web of Science ®Google Scholar
• Iyer SN , HydeDM, GiriSN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation24(5), 477–491 (2000).
   PubMed Web of Science ®Google Scholar
• Nakazato H , OkuH, YamaneSet al. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-α at the translational level. Eur. J. Pharmacol.446(1–3), 177–185 (2002).
   PubMed Web of Science ®Google Scholar
• Hostettler K , ZhongJ, TammMet al. Effect of pirfenidone on TGF-β-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis. Eur. Respir. J.44(Suppl. 58), 763 (2014).
   Google Scholar
• Azuma A , NukiwaT, TsuboiEet al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.171(9), 1040–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Taniguchi H , EbinaM, KondohYet al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J.35(4), 821–829 (2010).
   PubMed Web of Science ®Google Scholar
• Noble PW , AlberaC, BradfordWZet al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet377(9779), 1760–1769 (2011).
   PubMed Web of Science ®Google Scholar
• King TE , BradfordWZ, CastrobernardiniSet al. A Phase III trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med.370(22), 2083–2092 (2014).
   PubMed Web of Science ®Google Scholar
• Liu J , SongC, XiaoQet al. Fluorofenidone attenuates TGF-β1-induced lung fibroblast activation via restoring the expression of caveolin-1. Shock43(2), 201–207 (2015).
   PubMed Web of Science ®Google Scholar